Skip to main content

Neuropathic & Pelvic Pain Pharmacotherapy

Systemic and topical drugs used or studied for pelvic and neuropathic pain. Treatment depends on the diagnosis and pain mechanism: general neuropathic-pain recommendations cannot be applied automatically to IC/BPS, pelvic-floor myalgia or nonspecific chronic pelvic pain. Each hub distinguishes established indications, off-label options, negative trials and formulation-specific safety.

For IC/BPS-specific oral and intravesical pharmacotherapy see Bladder Pain & IC/BPS. For pelvic-floor physical therapy and behavioral approaches see Pelvic Floor PT.

  • GabapentinoidsGabapentin and pregabalin. Mixed pelvic-pain evidence, negative GaPP2 results, renal adjustment, respiratory and CNS risks, and individualized reassessment.
  • Tricyclic AntidepressantsAmitriptyline as an IC/BPS option; imipramine for selected refractory childhood enuresis; weak historical LUT evidence, cardiac and anticholinergic risks. Higher-dose subgroup findings do not establish a mandatory efficacy threshold.
  • SNRIsDuloxetine, venlafaxine and milnacipran. Distinct neuropathic-pain and psychiatric indications; duloxetine SUI evidence and European labeling; pelvic-pain uncertainty and urinary adverse effects.
  • NSAIDs & AnalgesicsIbuprofen, naproxen, celecoxib, acetaminophen, ketorolac. Renal-colic first-line; SKOPE RCT; the NOPIOIDS protocol (cystectomy / nephrectomy / RP) and ORIOLES 77% unused-opioid data; AUA expert-panel maximum-tablet table; phenazopyridine TRPM8 mechanism; nephrotoxicity considerations in the urologic patient.
  • Topical Compounded AgentsCompounded amitriptyline, baclofen, gabapentin, ketamine and lidocaine. Limited formulation-specific evidence, negative compounded-cream trial context, and local as well as systemic safety considerations.
  • Local AnestheticsLidocaine, bupivacaine, ropivacaine, mepivacaine. Twelve urologic domains — intraurethral jelly + cystoscopy, prostate biopsy network meta, intravesical lidocaine for IC/BPS (AUA Grade B), penile nerve block, vasectomy, PE topicals (Fortacin / EMLA), TAP block, retrograde stenting under LA, hydrodistension, plus a dedicated LAST safety section with the 20%-lipid-emulsion protocol.
  • AntispasmodicsDiazepam, cyclobenzaprine and baclofen. Limited pelvic-floor evidence, sedation and interaction risks; a companion to assessment and physical therapy, with off-label status made explicit.